GlassScriptPhysician profile
Aesha Mukesh Patel
NPI 1104245836
$3,947.00
in general payments reported to CMS, 2019-2025
36 companies · $1,711 in 2025
The $1,711 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $210 · 2022: $265 · 2023: $515 · 2024: $1,246 · 2025: $1,711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,377 · Long Term Medical Supply Or Device Loan: $59.94 · Education: $34.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,377.24 |
| Long Term Medical Supply Or Device Loan | $59.94 |
| Education | $34.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $477.34 | 2023-2025 | Freestyle Libre 3, Freestyle Insulinx, Perclose Prostyle |
| Lilly USA, LLC | $430.77 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $321.78 | 2023-2025 | Tepezza, Evenity, Prolia |
| Mannkind Corporation | $291.02 | 2021-2025 | Afrezza |
| Insulet Corporation | $247.04 | 2022-2025 | Omnipod |
| Amneal Pharmaceuticals LLC | $228.43 | 2023-2025 | Unithroid |
| Novo Nordisk INC | $188.46 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $165.16 | 2023-2025 | |
| Tandem Diabetes Care, INC. | $161.70 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $158.48 | 2021-2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $100.33 | 2021-2024 | |
| Cequr Corporation | $98.93 | 2025 | Cequr Simplicity |
| Neurocrine Biosciences, INC. | $98.80 | 2024-2025 | |
| Corcept Therapeutics | $95.19 | 2021-2025 | Korlym |
| Nevro Corp. | $91.34 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $75.87 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Madrigal Pharmaceuticals | $74.97 | 2025 | Rezdiffra |
| Sequel Med Tech, LLC | $58.87 | 2025 | Twiist |
| Horizon Therapeutics Plc | $53.34 | 2023 | Tepezza |
| Ibsa Pharma INC. | $51.34 | 2023-2025 | Tirosint, Licart, Flector |
| Xeris Pharmaceuticals, INC. | $42.73 | 2022 | |
| Kyowa Kirin, INC. | $41.27 | 2025 | |
| Ascensia Diabetes Care US INC. | $40.24 | 2024 | |
| Recordati_rare_diseases_inc. | $40.22 | 2023-2024 | Isturisa, Signifor Lar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.56 | 2021-2025 | Jardiance |
| Verity Pharmaceuticals INC. | $38.16 | 2024 | Tlando |
| Ascendis Pharma Endocrinology INC | $35.40 | 2024-2025 | Yorvipath |
| Bayer Healthcare Pharmaceuticals INC. | $33.75 | 2021-2025 | |
| Medtronic, INC. | $30.04 | 2021-2024 | Minimed 780g |
| Soleno Therapeutics, INC. | $29.71 | 2025 | Vykat Xr |
| Theracosbio, LLC | $25.14 | 2024 | Brenzavvy |
| Radius Health, INC. | $20.40 | 2022 | |
| Bard Peripheral Vascular, INC. | $17.34 | 2025 | Covera |
| Almatica Pharma LLC | $16.30 | 2025 | Teriparatide |
| Glaxosmithkline, LLC. | $14.18 | 2025 | Arexvy |
| Astrazeneca Pharmaceuticals LP | $13.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aesha Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.